Our Consultants and Partners have excellent academic backgrounds in biomedical and/or economic sciences combined with entrepreneurial spirit and extensive experience in world-leading health science companies. Target BioScience AG adheres strictly to the highest ethical standards and integrates client know-how.
Monika Lenzer serves as a Consultant in regulatory affairs and as a responsible person for quality management in Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP). She has broad experiences as a practical pharmacist since 2004 and as consultant for regulatory affairs since 2007. Monika Lenzer holds a Master degree as a pharmacist from the Ludwigs-Maximillian-University in Munich.
Margot Lieberherr has joined Target BioScience AG in 2023 as a consultant for quality assurance and serves as responsible person for quality management in Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP). She has broad practical experiences as pharmacist and in the pharmaceutical industry since 2004. Margot Lieberherr holds a Master degree as a pharmacist from the University of Graz (Austria).
Urs Heimgartner serves as a Consultant of Pricing & Reimbursement for Target BioScience AG. He has been an employee at Bayer (Schweiz) AG for 26 years and has served in many different functions, most recently as Head of Market Access. He has hands on experience in brining innovative products, despite the challenging environment, on the Reimbursement List (SL) of the BAG. Prior, he was Business Unit Manager Oncology and Hematology and successfully launched many pharmaceutical products such as Xarelto, Xofigo, Adempas, Stivarga and Kogenate SF. Urs Heimgartner has a PhD degree in Biotechnology from the ETH Zürich.
Jürgen Regenold has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of the global regulatory affair company Dr. Regenold GmbH as well as the founder of global regulatory group regulanet®. Jürgen Regenold manages all aspects of the business from strategic product development to regulatory affairs and market access. Previously he served in management of pharmaceutical product development and regulatory affairs. Jürgen Regenold holds a PhD degree as a pharmacist from the Albert-Ludwigs-University of Freiburg.
Patrik Frei has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of Venture Valuation AG, Switzerland. Since then he has been involved in over 350 valuations for investors as well as biotech, Pharma and medtech companies. He is also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company and a board member of Kleinkraftwerk Birseck AG (KKBN:Berne) a publicly quoted cleantech company. Patrik Frei graduated from the Business University of St. Gallen and completed his PhD thesis at the Swiss Federal Institute of Technology in Lausanne.
Patrick Kolb has been on the Advisory Board of Target BioScience AG since 2021. He is a Biotech startup expert in Europe with a strong focus on Germany, Austria and Switzerland. He has both global and local experience in General Management, Marketing, Sales, Medical Affairs and Market Access. Patrick Kolb has served as General Manager for Intercept, Astellas and Arvelle for Germany, Switzerland and Austria. His area of expertise are mainly focused on orphan medicinal products in various therapeutic fields, including Oncology. He holds an EMBA from HULT International Business Scholl and an MSc in Biology from University of Zurich.